KR102958344B1 - R-chop와 병용되는 치다마이드의 활용 및 약물 조합 - Google Patents
R-chop와 병용되는 치다마이드의 활용 및 약물 조합Info
- Publication number
- KR102958344B1 KR102958344B1 KR1020217018968A KR20217018968A KR102958344B1 KR 102958344 B1 KR102958344 B1 KR 102958344B1 KR 1020217018968 A KR1020217018968 A KR 1020217018968A KR 20217018968 A KR20217018968 A KR 20217018968A KR 102958344 B1 KR102958344 B1 KR 102958344B1
- Authority
- KR
- South Korea
- Prior art keywords
- chidamide
- chop
- combination
- treatment
- cell lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811394614.7 | 2018-11-20 | ||
| CN201811394614 | 2018-11-20 | ||
| PCT/CN2019/119170 WO2020103788A1 (zh) | 2018-11-20 | 2019-11-18 | 西达本胺联合r-chop的应用及联合药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210104059A KR20210104059A (ko) | 2021-08-24 |
| KR102958344B1 true KR102958344B1 (ko) | 2026-04-29 |
Family
ID=70741744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217018968A Active KR102958344B1 (ko) | 2018-11-20 | 2019-11-18 | R-chop와 병용되는 치다마이드의 활용 및 약물 조합 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12194054B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3884943B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7489397B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102958344B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN111195249B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019385373B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021009627A2 (cg-RX-API-DMAC7.html) |
| MY (1) | MY209036A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12021551138A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202105137RA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI768263B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020103788A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113813268A (zh) * | 2020-06-18 | 2021-12-21 | 苏州亚盛药业有限公司 | 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途 |
| CN112274509B (zh) * | 2020-12-02 | 2022-04-26 | 四川大学华西医院 | 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用 |
| CN118593502B (zh) * | 2024-05-24 | 2026-08-04 | 厦门大学附属第一医院 | 一种预防或治疗tp53突变双打击淋巴瘤的联合用药物组合物及其应用 |
| CN121513004B (zh) * | 2026-01-14 | 2026-04-03 | 首都医科大学附属北京友谊医院 | 一种治疗abc型弥漫性大b细胞淋巴瘤的组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| HRP20060080A2 (en) * | 2003-08-26 | 2006-07-31 | Sloan-Kettering Institute For Cancer Research | Method of treating cancer with hdac inhibitors |
| CN101146548A (zh) * | 2005-02-15 | 2008-03-19 | 诺华疫苗和诊断公司 | 化疗药、il-2和任选的抗cd20抗体联用治疗淋巴瘤的方法 |
| CN101470112A (zh) * | 2007-12-28 | 2009-07-01 | 上海交通大学医学院附属瑞金医院 | 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物 |
| CN103833626B (zh) | 2012-11-27 | 2015-11-25 | 深圳微芯生物科技有限责任公司 | 西达本胺的晶型及其制备方法与应用 |
| TWI808055B (zh) * | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| MX2019000864A (es) | 2016-07-20 | 2019-06-03 | Univ Columbia | Activadores de histona acetiltransferasa y sus composiciones y usos. |
| CN107157978B (zh) * | 2017-05-24 | 2021-06-18 | 中国药科大学 | 治疗ebv+dlbcl和dlbcl的药物及组合物 |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
-
2019
- 2019-03-25 CN CN201910228406.8A patent/CN111195249B/zh active Active
- 2019-03-25 CN CN202311474046.2A patent/CN117797149A/zh active Pending
- 2019-11-18 MY MYPI2021002751A patent/MY209036A/en unknown
- 2019-11-18 AU AU2019385373A patent/AU2019385373B2/en active Active
- 2019-11-18 SG SG11202105137RA patent/SG11202105137RA/en unknown
- 2019-11-18 KR KR1020217018968A patent/KR102958344B1/ko active Active
- 2019-11-18 JP JP2021551329A patent/JP7489397B2/ja active Active
- 2019-11-18 TW TW108141826A patent/TWI768263B/zh active
- 2019-11-18 US US17/295,494 patent/US12194054B2/en active Active
- 2019-11-18 BR BR112021009627-2A patent/BR112021009627A2/pt unknown
- 2019-11-18 WO PCT/CN2019/119170 patent/WO2020103788A1/zh not_active Ceased
- 2019-11-18 EP EP19887480.2A patent/EP3884943B1/en active Active
-
2021
- 2021-05-19 PH PH12021551138A patent/PH12021551138A1/en unknown
Non-Patent Citations (1)
| Title |
|---|
| Blood 130 (2017): 4126* |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202033194A (zh) | 2020-09-16 |
| AU2019385373B2 (en) | 2025-08-21 |
| SG11202105137RA (en) | 2021-06-29 |
| CN111195249B (zh) | 2023-11-28 |
| KR20210104059A (ko) | 2021-08-24 |
| CA3120207A1 (en) | 2020-05-28 |
| US12194054B2 (en) | 2025-01-14 |
| JP2022511126A (ja) | 2022-01-28 |
| CN111195249A (zh) | 2020-05-26 |
| US20220016147A1 (en) | 2022-01-20 |
| EP3884943B1 (en) | 2024-07-17 |
| PH12021551138A1 (en) | 2022-02-21 |
| EP3884943A1 (en) | 2021-09-29 |
| JP7489397B2 (ja) | 2024-05-23 |
| EP3884943A4 (en) | 2022-07-06 |
| BR112021009627A2 (pt) | 2021-08-10 |
| MY209036A (en) | 2025-06-17 |
| CN117797149A (zh) | 2024-04-02 |
| WO2020103788A1 (zh) | 2020-05-28 |
| TWI768263B (zh) | 2022-06-21 |
| AU2019385373A1 (en) | 2021-06-24 |
| EP3884943C0 (en) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12194054B2 (en) | Application of Chidamide in combination with R-CHOP, and drug combination | |
| Munakata et al. | Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma | |
| CN108883109A (zh) | 用于治疗急性髓性白血病的联合疗法 | |
| Peterson et al. | Intensive five‐drug combination chemotherapy for adult acute non‐lymphocytic leukemia | |
| CN113908159A (zh) | 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途 | |
| Oh et al. | The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate | |
| CA2944088C (en) | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake | |
| Hansen et al. | Phase III study of intermittent 5‐drug regimen (VBCMP) versus intermittent 3‐drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis | |
| Pelosi et al. | The growing role of the BH3 mimetic drug venetoclax in the therapy of acute myeloid leukemia | |
| CN107157978B (zh) | 治疗ebv+dlbcl和dlbcl的药物及组合物 | |
| CA3120207C (en) | Application of chidamide in combination with r-chop, and drug combination | |
| RU2802620C2 (ru) | Применение хидамида в комбинации с R-CHOP и комбинация лекарственных средств | |
| HK40057612A (en) | Application of chidamide in combination with r-chop, and drug combination | |
| HK40057612B (en) | Application of chidamide in combination with r-chop, and drug combination | |
| CN111228264A (zh) | 西达本胺联合cgb以及自体造血干细胞的应用及联合药物 | |
| US20110301102A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| CN111195250A (zh) | 西达本胺联合dice的应用及联合药物 | |
| US20240277663A1 (en) | Pharmaceutical kits and uses thereof for treating colorectal cancer | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| CA3190276A1 (en) | Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof | |
| Zheng et al. | Strategy to further increase of cure rate in acute promyelocytic leukaemia: low-dose all-trans retinoic acid and sequential maintenance cycle Correspondence. | |
| MX2011009301A (es) | Composiciones y metodos para tratar sindrome mielodisplasico. | |
| Prescott | Advances in the Treatment of Hematological Malignancies | |
| WO2013019222A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| Guida | Rituximab in advanced rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |